Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory

We came crossed a bullish thesis connected Recursion Pharmaceuticals, Inc. connected r/stocks by  Antique-Reference585. In this article, we volition summarize the bulls’ thesis connected RXRX. Recursion Pharmaceuticals, Inc.'s stock was trading astatine $4.67 arsenic of January 16th.

Wichy/Shutterstock.com

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages successful the decoding biology and chemistry by integrating technological innovations crossed biology, chemistry, automation, information science, and engineering to industrialize cause find successful the United States.

RXRX is emerging as a compelling concern successful the AI-driven pharmaceutical space, peculiarly arsenic macro uncertainties, including the ongoing Powell probe and imaginable challenges to U.S. recognition credibility, make turbulence successful broader markets. While large-cap tech similar $GOOG continues to grow—recently surpassing a $4 trillion marketplace cap—these behemoths are improbable to treble from here. The existent upside lies with companies leveraging AI successful high-growth niches, and Recursion fits this profile.

Unlike peers specified arsenic $LLY, which has partnered with Nvidia connected a $1 cardinal AI pharmaceutical inaugural but is mostly priced in, oregon $ILMN, which has transformed from a hardware supplier to a high-margin AI information services supplier but has already doubled since its low, $RXRX offers some strategical positioning and an charismatic valuation.

Recursion is simply a nonstop equity spouse with Nvidia, serving arsenic a halfway state successful AI-driven cause discovery, with its proprietary Recursion OS integrating immense biologic imaging information into a closed-loop AI experimentation platform—a uncommon capableness astatine petabyte scale.

Under CEO Chris Gibson, the institution has focused connected "translating biology into hunt problems," mirroring Nvidia and Google’s attack to AI, and has built the BioHive-2 supercomputer, the industry’s astir precocious AI platform. Coupled with a important currency reserve lasting done 2027, this provides fiscal stableness and operational runway for assertive growth.

Trading successful $RXRX is presently nether the radar, offering a low-demand introduction constituent with the imaginable for important upside, including the anticipation of doubling erstwhile superior rotates into the AI pharmaceutical sector, making it a standout accidental for investors seeking high-risk, high-reward exposure.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the company’s CRISPR cistron editing leadership, Casgevy’s commercial potential, and a beardown pipeline. CRSP’s banal terms has appreciated by astir 30.60% since our sum as the thesis played out. Antique-Reference585 shares a akin absorption connected high-growth biotech but emphasizes Recursion Pharmaceuticals ($RXRX) and its AI-driven level with Nvidia partnership.